Journal
INTERNATIONAL JOURNAL OF ONCOLOGY
Volume 56, Issue 4, Pages 889-899Publisher
SPANDIDOS PUBL LTD
DOI: 10.3892/ijo.2020.4982
Keywords
chimeric antigen receptor-T cell; gastric cancer; immunotherapy; solid tumor
Categories
Funding
- Fundamental Research Funds of the Central Universities [lzujbky-2019-cd06]
- Cuiying Science and Technology Innovation Project of Lanzhou City [CY2017-ZD03]
- National Natural Science Foundation of China [31670847]
Ask authors/readers for more resources
Gastric cancer (GC) is one of the most frequently diagnosed digestive malignancies and is the third leading cause of cancer-associated death worldwide. Delayed diagnosis and poor prognosis indicate the urgent need for new therapeutic strategies. The success of chimeric antigen receptor (CAR) T-cell therapy for chemotherapy-refractory hematological malignancies has inspired the development of a similar strategy for GC treatment. Although using CAR T-cells against GC is not without difficulty, results from preclinical studies remain encouraging. The current review summarizes relevant preclinical studies and ongoing clinical trials for the use of CAR T-cells for GC treatment and investigates possible toxicities, as well as current clinical experiences and emerging approaches. With a deeper understanding of the tumor microenvironment, novel target epitopes and scientific-technical progress, the potential of CAR T-cell therapy for GC is anticipated in the near future.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available